Use of the Workbook Method to estimate the prevalence of chronic hepatitis B infections in the European Union and European Economic Area, 2022
Open Access
- 9 April 2026
- journal article
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 31 (14) , 2500322
Abstract
BACKGROUND: Up-to-date estimates of chronic hepatitis B virus (HBV) prevalence in both general and key populations are challenging to obtain because of underdiagnosis, heterogeneous surveillance systems and underrepresentation of key populations. AIM: We aimed to test the Workbook Method to estimate chronic HBV prevalence in 2022 across the EU/EEA, by country and among men who have sex with men (MSM), people who inject drugs (PWID) and migrants. METHODS: We used the Robert Koch Institute’s version of the Joint United Nations Programme on HIV/AIDS (UNAIDS) Workbook Method to generate HBV prevalence estimates for each EU/EEA country and for MSM, PWID and migrants within each country. We combined data on population size and HBV prevalence for each population group gathered from scientific sources and reviewed by the European Centre for Disease Prevention and Control’s hepatitis national contact points. RESULTS: Overall, 0.7% (lower bound–upper bound: 0.5–0.9%) of the EU/EEA population (3,226,000 (2,397,000–4,149,000) individuals) were estimated to be living with HBV in 2022. National HBV prevalence ranged from 0.1% (0.1–1.0%) to 3.1% (2.8–3.3%). Prevalence estimates varied from 0.8% (0.5–1.0%) to 10.5% (9.3–11.9%) for migrants, < 0.1% to 8.7% (lower and upper bounds not available) for PWID and from < 0.1% (< 0.1– < 0.1%) to 10.5% (10.2–10.8%) for MSM. DISCUSSION: Despite limitations, including the inability to address overlapping populations, these estimates confirm substantial chronic HBV prevalence in the EU/EEA, with considerable variation between countries and population groups. This relatively straightforward method offers an alternative means of generating HBV prevalence estimates.Keywords
This publication has 19 references indexed in Scilit:
- Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling studyThe Lancet Gastroenterology & Hepatology, 2023
- The disease burden of hepatitis B and hepatitis C from 2015 to 2030: the long and winding roadJournal of Hepatology, 2022
- Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019The Lancet Gastroenterology & Hepatology, 2022
- Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general populationEpidemiology and Infection, 2019
- Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic reviewEpidemiology and Infection, 2017
- Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013The Lancet, 2015
- Hepatitis C virus prevalence in The Netherlands: migrants account for most infectionsEpidemiology and Infection, 2012
- Estonia at the Threshold of the Fourth Decade of the AIDS Era in EuropeAIDS Research and Human Retroviruses, 2011
- Hepatitis B vaccines: WHO position paper—RecommendationsVaccine, 2010
- The expanded programme on immunization calendar in Poland.Vaccine, 2000